Vaccination against COVID-19

The Convacel vaccine, the world's first registered vaccine against COVID—19 based on a nucleocapsid protein, is available at the European Medical Center.

What is the difference between the new vaccine?

The previous generation of vaccines were aimed at producing neutralizing antibodies to the coronavirus surface protein, which is most susceptible to mutations. The action of "Konvacel" is directed at another, nucleocapsid N protein of the SARS-CoV-2 virus, which is almost not subject to mutational changes and remains identical for all variants of the B virus. This gives the vaccine a great advantage, allowing it to provide reliable protection against most strains.

How is vaccination carried out?

"Convacel" is administered once.The period of immunity preservation after vaccination, proven by observations, is more than one year. The drug is used for vaccination of adults from 18 years of age, including approved for use in patients over 60 years of age.

How to evaluate immunity before vaccination?

If you are in doubt whether to get vaccinated, there is an opportunity to assess your immune status in relation to COVID-19. Tests for the determination of IgM and IgG antibodies, as well as for the assessment of T-cell immunity, are available at the European Medical Center. It is believed that the higher the level of antibodies in the blood, the lower the risk of re-infection with the virus, as well as the likelihood of severe disease and complications of COVID-19.